Evidence map›Paper›PMID 19631360›Full record

ArticleVirology2009

Interaction of HCMV UL84 with C/EBPalpha transcription factor binding sites within oriLyt is essential for lytic DNA replication.

Dominique Kagele, Yang Gao, Kate Smallenburg, Gregory S Pari

Abstract read
In one paragraph

Article in Virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dominique KageleUniversity of Nevada-Reno School of Medicine, Department of Microbiology and Immunology and the Cell and Molecular Biology Graduate Program, Howard Bldg. 210, Reno, NV 89557, USA.
Yang Gao
Kate Smallenburg
Gregory S Pari

Funding

CHARACTERIZATION OF HCMV UL84R01AI045096 · NIAID · UNIVERSITY OF NEVADA RENO · PI ROSSETTO, CYPRIAN CONSTANCE · 2000 to 2014
$4.6M
NIAID NIH HHS AI45096NIAID NIH HHS R01 AI045096
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) lytic DNA replication is initiated at the cis-acting oriLyt region and requires six core replication proteins along with UL84 and IE2. Although UL84 is thought to be the replication initiator protein, little is known about its interaction with oriLyt. We have now performed chromatin immunoprecipitation assays (ChIP) using antibodies specific to UL84, IE2, UL44, CCAAT/enhancer binding protein (C/EBPalpha) and PCR primers that span the entire oriLyt region to reveal an evaluation of specific protein binding across oriLyt. UL84 interacted with several regions of oriLyt that contain C/EBPalpha transcription factor binding sites. Mutation of either of one of C/EBPalpha (92,526 or 92,535) sites inactivated oriLyt and resulted in the loss of binding of UL84. These data reveal the regions of interaction within oriLyt for several key replication proteins and show that the interaction between UL84 and C/EBPalpha sites within oriLyt is essential for lytic DNA replication.

Indexed as

Base SequenceBinding SitesCCAAT-Enhancer-Binding Protein-alphaCell LineCytomegalovirusDNA-Binding ProteinsDNA ReplicationDNA, ViralHumansImmediate-Early ProteinsIn Vitro TechniquesMutagenesis, Site-DirectedOptic Nerve InjuriesRecombinant ProteinsTrans-ActivatorsViral ProteinsCCAAT-Enhancer-Binding Protein-alphaDNA-Binding ProteinsDNA, ViralICP36 protein, CytomegalovirusIE2 protein, CytomegalovirusImmediate-Early ProteinsoriLyt protein, Human cytomegalovirusRecombinant ProteinsTrans-ActivatorsUL84 protein, CytomegalovirusViral Proteins

Identifiers

PMID19631360
PMCPMC2740927

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.